

# Gene-expression profile associated with drug resistance in adult acute myeloid Leukemia

Michael Heuser,<sup>1</sup> Luzie U. Wingen,<sup>2</sup> Doris Steinemann,<sup>2</sup> Gunnar Cario,<sup>3</sup> Nils von Neuhoff,<sup>3</sup> Marcel Tauscher,<sup>2</sup> Lars Bullinger,<sup>5</sup> Juergen Krauter,<sup>1</sup> Gerhard Heil,<sup>4</sup> Hartmut Dohner,<sup>5</sup> Brigitte Schlegelberger,<sup>2</sup> Arnold Ganser<sup>1</sup>

<sup>1</sup>Department of Hematology, Hemostaseology and Oncology; <sup>2</sup>Institute of Cell and Molecular Pathology; <sup>3</sup>Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; <sup>4</sup>Department of Hematology and Oncology, Märkische Kliniken Lüdenscheid, Lüdenscheid, Germany; <sup>5</sup>Department of Internal Medicine III, University of Ulm, Ulm, Germany

Citation: Heuser M, Wingen LU, Steinemann D, Cario G, von Neuhoff N, Tauscher M, Bullinger L, Krauter J, Heil G, Dohner H, Schlegelberger B, Ganser A. Gene-Expression Profile Associated with Drug Resistance in Adult Acute Myeloid Leukemia *Haematologica* 2005;90:1484-1492.

Online Supplementary Table 1. Characteristics of clusters 1 and 2.

Characteristic	cluster 1 N=18	cluster 2 N=15	p-value
Poor Response - no.	5/18	6/15	0.49
Age – median (years)	46.5	50.	
range (years)	18-60	22-60	
WBC count – mean (cells/μl)	29,861	38,580	0.58
FAB 0-2 / 4-5 – no.	12 / 6	5 / 10	0.08
Karyotype			
favorable – no.	2	1	
intermediate – no.	15	12	
adverse – no.	1	2	0.69
OS median - days	486	485	0.68

Online Supplementary Figure 1.



